NCT04776395 2026-04-17
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Phase 2 Recruiting
Clinical Trials
15 trialsNCT02960555 2026-04-15
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05955508 2026-04-13
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT06140524 2026-04-08
LINKER-MGUS1
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT03236428 2026-03-27
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05767359 2026-03-12
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05014646 2026-03-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04850846 2026-02-09
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01237054 2026-02-06
Imaging in MGUS, SMM and MM
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06762769 2025-08-01
MODIFY
University College, London
Phase 2 Recruiting
NCT02316106 2025-04-27
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT05469893 2025-04-24
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Recruiting